BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

The FIX is in: Uniqure NAbs FDA clearance for gene therapy Hemgenix in hemophilia B
The U.S. FDA gave its go-ahead for Hemgenix (etranacogene dezaparvovec-drlb), Uniqure NV’s one-time gene therapy – the first for the treatment of adults 18 and older living...

More in BioWorld

BioWorld MedTech

Microport’s intracranial artery stent granted priority review in China
Microport Neurotech Ltd.’s intracranial visualized stent Rebridge has been included in the green channel, a priority review for medical devices, by China’s NMPA.

More in BioWorld MedTech

BioWorld Science

Cell lines from XXY donor enable new view on sex-specific biology
Israeli researchers have created cell lines, using cells donated by an individual with Klinefelter syndrome, that had different combinations of sex chromosomes but were...

More in BioWorld Science

BioWorld Asia

Tenacia acquires seizure therapy from Marinus in $266M deal
Tenacia Biotechnology Co. Ltd. has acquired exclusive greater China rights to certain formulations of Marinus Pharmaceuticals Inc.’s seizure therapy, ganaxolone (Ztalmy),...

More in BioWorld Asia

BioWorld Insider Podcast

BioWorld staff writer Lee Landenberger talks with James Lanthier, the CEO of Mindset Pharma, which is developing what it calls “next-generation” psychedelic medicines to treat neurological and psychiatric disorders.